Komori Takahiro, Kosaka Takeo, Tanaka Tomoki, Watanabe Keitaro, Yasumizu Yota, Mikami Shuji, Oya Mototsugu
Department of Urology, Keio University School of Medicine Tokyo, Japan.
Department of Radiology, Keio University School of Medicine Tokyo, Japan.
Am J Clin Exp Urol. 2023 Aug 15;11(4):339-343. eCollection 2023.
Retinoblastoma transcriptional corepressor 1 (RB1) and tumor protein p53 (TP53) are well-known tumor suppressor genes; their alterations are associated with poor prognosis in human malignancies and quite rare in locally recurrent cases. The patient was a 58-year-old man who was diagnosed with cT1cN0M0 prostate cancer with Gleason score of 3+3=6 and underwent brachytherapy as the initial treatment. Local recurrence was detected in the left lobe of the prostate 154 months later and whole-exome sequencing that was performed at the request of the patient revealed RB1 loss-of-heterozygosity and TP53 p.I162Rfs*27 mutations. He underwent salvage focal brachytherapy with I seeds and serum prostate-specific antigen levels has been stabilized without any genitourinary or gastrointestinal toxicity.
视网膜母细胞瘤转录共抑制因子1（RB1）和肿瘤蛋白p53（TP53）是众所周知的肿瘤抑制基因；它们的改变与人类恶性肿瘤的不良预后相关，并且在局部复发病例中相当罕见。该患者为一名58岁男性，被诊断为cT1cN0M0期前列腺癌，Gleason评分3+3=6，初始治疗接受近距离放射治疗。154个月后在前列腺左叶检测到局部复发，应患者要求进行的全外显子测序显示RB1杂合性缺失和TP53 p.I162Rfs*27突变。他接受了I粒子挽救性局部近距离放射治疗，血清前列腺特异性抗原水平已稳定，未出现任何泌尿生殖系统或胃肠道毒性。
